Orthopedic implant specialist CJ Medtech announced on the 17th that it achieved a turnaround to profitability, posting a cumulative consolidated revenue of 35.73 billion won, operating profit of 3.49 billion won, and net profit of 3.22 billion won for the first three quarters of this year. As a result, CJ Medtech is expected to post its highest-ever annual performance since its founding.
On a separate basis, revenue for the same period was 20.73 billion won, up 26% year-on-year. Operating profit reached 2.38 billion won, an 81% increase from the previous year, and net profit also turned positive at 4.85 billion won.
This improvement in performance was largely due to strategic collaboration with its parent company, CGBio. Leveraging CGBio's distribution network and CJ Medtech's product capabilities and production capacity, domestic sales were strengthened, leading to a revenue increase of approximately 1.8 billion won compared to the same period last year. In particular, the "Velo" lineup of spinal bone grafts, which combines CJ Medtech's orthopedic implant technology with CGBio's regenerative medicine technology, posted cumulative sales of 1.4 billion won in the third quarter, quickly establishing a foothold in the market.
Subsidiary GDS, which was absorbed through a merger in the first half of the year, contributed to consolidated results by generating an additional 1 billion won in sales through digital dentistry-based products. Allabutment, acquired in May, secured 800 million won in sales, further accelerating the expansion of the dental implant portfolio.
The company is also showing steady growth in global markets. The U.S. subsidiary achieved an export increase of approximately 1 billion won year-on-year, driven by the expansion of new clients and product lineups. Notably, CJ Medtech is rapidly securing new clients in major markets such as the United States, with its high-value-added products like cervical cages receiving positive evaluations from medical professionals. Recently, the spinal fusion device "UniSpace TPLIF Cage" obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA), accelerating the company’s global market push. Developed with a structure optimized for CGBio's next-generation bone substitute "NOVOSIS PUTTY," clinical synergy is also anticipated, and the product is expected to positively influence the speed of FDA approval in the United States.
In addition, the company is accelerating its entry into the regenerative medicine-based fracture treatment market, based on an exclusive supply agreement for "NOVOSIS Trauma" with global medical device company Johnson & Johnson MedTech.
CJ Medtech CEO Yoo Hyunseung said, "We are achieving balanced growth across all sectors, from domestic spinal and dental implant businesses to new bone graft products and overseas exports," adding, "We will further strengthen our competitiveness through synergies with CGBio, a strategy focused on high-value-added products, and expansion into new businesses such as digital dentistry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
